A population-based study of active and drug-resistant epilepsies in Northern Italy

被引:27
|
作者
Giussani, Giorgia [1 ]
Canelli, Valentina [1 ]
Bianchi, Elisa [1 ]
Franchi, Carlotta [1 ]
Nobili, Alessandro [1 ]
Erba, Giuseppe [2 ]
Beghi, Ettore [1 ]
机构
[1] IRCCS Ist Ric Farmacol Mario Negri, Milan, Italy
[2] Univ Rochester, Dept Neurol, SEC, Rochester, NY USA
关键词
Prevalence; Epilepsy; Drug resistance; Medical practitioners; REFRACTORY EPILEPSY; ILAE COMMISSION; PREVALENCE; CHILDHOOD; ONSET; LONG; INTRACTABILITY; ADULTS; DUTCH;
D O I
10.1016/j.yebeh.2015.11.021
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Drug-resistant epilepsy (DRE) is defined by the International League Against Epilepsy as a failure of adequate trials of two tolerated, appropriately chosen, and used antiepileptic drugs to achieve sustained seizure freedom. Our aim was to calculate the following: (1) the prevalence of active epilepsy and DRE in a well-defined population of Northern Italy and (2) the proportion of incident cases developing DRE. The study population (146,506; year 2008) resided in the province of Lecco, Northern Italy. The medical records of 123 general practitioners were reviewed to identify patients with epilepsy, diagnosed by a neurologist during the period 2000-2008. The point prevalence of active epilepsy and DRE was calculated on December 31, 2008. A total of 747 prevalent patients with epilepsy, 684 patients with active epilepsy, and 342 incident cases were identified. The frequency of DRE was 15.6% (107/684) of all active epilepsies and 10.5% (36/342) of incident cases. The point prevalence was 0.73 per 1000. The standardized prevalence of DRE was 0.7 per 1000 (Italian population) and 0.8 per 1000 (world population). Our data indicate that 1/6 patients with active epilepsy in the general population has DRE, and 1/10 patients with newly diagnosed epilepsy will develop DRE within nine years from the diagnosis. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:30 / 37
页数:8
相关论文
共 50 条
  • [1] The Epidemiology of Drug-Resistant Epilepsy in Northern Italy
    Beghi, Ettore
    Giussani, Giorgia
    Canelli, Valentina
    Bianchi, Elisa
    Franchi, Carlotta
    Nobili, Alessandro
    Erba, Giuseppe
    [J]. NEUROLOGY, 2016, 86
  • [2] VIGABATRIN IN DRUG-RESISTANT EPILEPSIES
    FROSCHER, W
    RAUBER, A
    ROTHMEIER, J
    STEINERT, T
    [J]. AKTUELLE NEUROLOGIE, 1992, 19 : S48 - S49
  • [3] A population-based study of risk factors for drug-resistant TB in British Columbia
    Moniruzzaman, A.
    Elwood, R. K.
    Schulzer, M.
    FitzGerald, J. M.
    [J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2006, 10 (06) : 631 - 638
  • [4] New therapeutic targets to develop molecules active in drug-resistant epilepsies
    SidAhmed-Mezi, Mounia
    Pumain, Rene
    Louvel, Jacques
    Sokoloff, Pierre
    Laschet, Jacques
    [J]. EPILEPSIA, 2010, 51 : 43 - 47
  • [5] Epidemiology of drug-resistant epilepsies.
    Jallon, P
    [J]. REVUE NEUROLOGIQUE, 2004, 160 : S22 - S30
  • [6] Genetic characterisation of drug-resistant Mycobacterium tuberculosis in rural China: a population-based study
    Hu, Y.
    Hoffner, S.
    Jiang, W.
    Wang, W.
    Xu, B.
    [J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2010, 14 (02) : 210 - 216
  • [7] Cognitive impairment in premotor drug-resistant epilepsies
    Pasnicu, A
    Trebon, P
    De Grissac-Moriez, N
    Seigneuret, E
    Scarabin, JM
    Biraben, A
    [J]. EPILEPSIA, 2005, 46 : 328 - 328
  • [8] EFFICACY AND SAFETY OF TOPIRAMATE IN DRUG-RESISTANT EPILEPSIES
    LUEF, G
    BAUER, G
    [J]. EPILEPSIA, 1995, 36 : S151 - S151
  • [9] Invasive neuromodulation in the treatment of drug-resistant epilepsies
    Lorand, Eross
    Laszlo, Entz
    Daniel, Fabo
    [J]. ORVOSI HETILAP, 2015, 156 (52) : 2103 - 2109
  • [10] Management of drug-resistant epilepsies in children.
    Caraballo, Roberto H.
    [J]. MEDICINA-BUENOS AIRES, 2022, 82 : 7 - 12